Aubagio teriflunomide regulatory update

The European Commission approved an MAA from Sanofi for Aubagio teriflunomide to treat relapsing-remitting multiple sclerosis (RRMS). Sanofi said it plans to launch Aubagio in Europe "in the coming months," with the first launch slated for October in Germany. Sanofi's Genzyme Corp. unit already markets the dihydroorotate dehydrogenase (DHODH) inhibitor in the U.S., Australia and Argentina to treat relapsing MS. The drug is also approved in Chile and South Korea. ...